ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancer
(MedPage Today) -- MADRID -- Disease-free survival (DFS) in resectable ALK-positive non-small cell lung cancer (NSCLC) improved by 76% with adjuvant alectinib (Alecensa) compared with chemotherapy, according to a randomized trial.
Across disease...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Lung Cancer | Non-Small Cell Lung Cancer